Purchase this article with an account.
E. R. Craven, T. Lin, T. Mundorf, M. Tepedino, R. Frenkel, J. Walt, C.-C. Liu, A. Batoosingh; Patient- and Physician-Reported Satisfaction Following Treatment With Bimatoprost 0.01% or Vehicle in Patients With Glaucoma or Ocular Hypertension (OHT). Invest. Ophthalmol. Vis. Sci. 2010;51(13):170.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The efficacy of and safety of bimatoprost 0.01% has been reported in a phase 2 study of patients with glaucoma or OHT whose intraocular pressure (IOP) was adequately controlled with latanoprost. The purpose of this analysis was to evaluate patient- and physician-reported outcomes with treatment in that study.
In this double-masked, multicenter, parallel-group study, 222 patients were enrolled. The mITT population consisting of randomized and treated patients who had the primary safety variable, macroscopic hyperemia, evaluated at baseline and Month 1 visits included 147 and 71 patients randomized (2:1) to once-daily bimatoprost 0.01% or vehicle, respectively. Patients assessed acceptability of treatment by a series of 6 questions: 2 relating to willingness to continue treatment and 4 relating to eye appearance. Physicians answered 2 questions regarding willingness to continue use of study medication. Wilcoxon rank-sum test was used to compare groups.
After 1 month of treatment, a statistically significant difference was observed in patients’ or physicians’ response of receiving or prescribing the randomized treatment in 4 categories (P<.001, see Table below) Change in eye appearance was reported by 7 (5%) patients in the bimatoprost arm and by 4 (6%) patients in the vehicle arm.
Patient and physician acceptability of treatment significantly favored bimatoprost over vehicle.
This PDF is available to Subscribers Only